Adverts

Open Access Articles- Top Results for Acipimox

Acipimox

</th></tr>
Acipimox
Skeletal formula
Ball-and-stick model
Systematic (IUPAC) name
5-carboxy-2-methyl-1-oxidopyrazin-1-ium
Clinical data
AHFS/Drugs.com International Drug Names
Oral
Identifiers
51037-30-0 7pxY
C10AD06
PubChem CID 5310993
ChemSpider 4470534 7pxY
UNII K9AY9IR2SD 7pxY
KEGG D07190 7pxY
ChEMBL CHEMBL345714 7pxY
Chemical data
Formula C6H6N2O3
154.124 g/mol
 14pxY (what is this?)  (verify)

Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout.

Brands available : Acipicap from Zydus Cadila